Safety and Efficacy of EIK1001-006 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.
NCT 06697301 Brief Summary The study is for patients with advanced melanoma…
Read more arrow_forwardNCT 06697301 Brief Summary The study is for patients with advanced melanoma…
Read more arrow_forwardACTRN 12621001537842 Brief Summary This trial aims to determine whether NOX66 (idronoxil)…
Read more arrow_forwardNCT 05544552 Brief Summary The purpose of this study is to evaluate…
Read more arrow_forwardNCT 04450732 Brief Summary Phase I Dose Finding Study for GQ1001 in…
Read more arrow_forwardACTRN 12623001216606 Brief Summary The purpose of the study is to investigate…
Read more arrow_forwardNCT 06736704 Brief Summary This study is testing a new medicine, SNV4818,…
Read more arrow_forwardNCT 05614258 Brief Summary ADG206 is an activatable prodrug form of a…
Read more arrow_forwardNCT 05267626 Brief Summary This is a first in human, open-label, multi-center…
Read more arrow_forwardNCT 06819735 Brief Summary This is a phase 1/2, dose-escalation and cohort-expansion…
Read more arrow_forwardNCT 03947385 Brief Summary This is a Phase 1/2, multi-center, open-label basket…
Read more arrow_forwardNCT 07156136 Brief Summary Phase 1 First-in-human study of the safety and…
Read more arrow_forwardNCT 04665206 Brief Summary This is an open-label, dose escalation and expansion…
Read more arrow_forwardNCT 05727904 Brief Summary This is a Phase 3, multicenter, open-label, randomized,…
Read more arrow_forward